These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Differential post-translational modifications of transthyretin in Alzheimer's disease: a study of the cerebral spinal fluid. Biroccio A; Del Boccio P; Panella M; Bernardini S; Di Ilio C; Gambi D; Stanzione P; Sacchetta P; Bernardi G; Martorana A; Federici G; Stefani A; Urbani A Proteomics; 2006 Apr; 6(7):2305-13. PubMed ID: 16552785 [TBL] [Abstract][Full Text] [Related]
6. Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease. Lee JW; Namkoong H; Kim HK; Kim S; Hwang DW; Na HR; Ha SA; Kim JR; Kim JW BMC Neurol; 2007 Jun; 7():14. PubMed ID: 17565664 [TBL] [Abstract][Full Text] [Related]
8. Both plasma retinol-binding protein and haptoglobin precursor allele 1 in CSF: candidate biomarkers for the progression of normal to mild cognitive impairment to Alzheimer's disease. Jung SM; Lee K; Lee JW; Namkoong H; Kim HK; Kim S; Na HR; Ha SA; Kim JR; Ko J; Kim JW Neurosci Lett; 2008 May; 436(2):153-7. PubMed ID: 18378077 [TBL] [Abstract][Full Text] [Related]
9. Continuous CSF drainage in AD: results of a double-blind, randomized, placebo-controlled study. Silverberg GD; Mayo M; Saul T; Fellmann J; Carvalho J; McGuire D Neurology; 2008 Jul; 71(3):202-9. PubMed ID: 18525029 [TBL] [Abstract][Full Text] [Related]
10. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456 [TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease. Montine TJ; Markesbery WR; Morrow JD; Roberts LJ Ann Neurol; 1998 Sep; 44(3):410-3. PubMed ID: 9749613 [TBL] [Abstract][Full Text] [Related]
12. Transthyretin as a potential CSF biomarker for Alzheimer's disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors. Schultz K; Nilsson K; Nielsen JE; Lindquist SG; Hjermind LE; Andersen BB; Wallin A; Nilsson C; Petersén A Eur J Neurol; 2010 Mar; 17(3):456-60. PubMed ID: 19922456 [TBL] [Abstract][Full Text] [Related]
13. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease. Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452 [TBL] [Abstract][Full Text] [Related]
14. Quantitative EEG in progressing vs stable mild cognitive impairment (MCI): results of a 1-year follow-up study. Luckhaus C; Grass-Kapanke B; Blaeser I; Ihl R; Supprian T; Winterer G; Zielasek J; Brinkmeyer J Int J Geriatr Psychiatry; 2008 Nov; 23(11):1148-55. PubMed ID: 18537220 [TBL] [Abstract][Full Text] [Related]
15. Human serum transthyretin levels correlate inversely with Alzheimer's disease. Han SH; Jung ES; Sohn JH; Hong HJ; Hong HS; Kim JW; Na DL; Kim M; Kim H; Ha HJ; Kim YH; Huh N; Jung MW; Mook-Jung I J Alzheimers Dis; 2011; 25(1):77-84. PubMed ID: 21335655 [TBL] [Abstract][Full Text] [Related]
16. Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease. Hampel H; Shen Y Scand J Clin Lab Invest; 2009; 69(1):8-12. PubMed ID: 18609117 [TBL] [Abstract][Full Text] [Related]
17. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease. van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Finehout EJ; Franck Z; Choe LH; Relkin N; Lee KH Ann Neurol; 2007 Feb; 61(2):120-9. PubMed ID: 17167789 [TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease? Palumbo B; Siepi D; Sabalich I; Tranfaglia C; Parnetti L Funct Neurol; 2008; 23(2):93-6. PubMed ID: 18671910 [TBL] [Abstract][Full Text] [Related]
20. Usability of cerebrospinal fluid biomarkers in a tertiary memory clinic. Brandt C; Bahl JC; Heegaard NH; Waldemar G; Johannsen P Dement Geriatr Cogn Disord; 2008; 25(6):553-8. PubMed ID: 18536519 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]